Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Not yet recruiting 3Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Esophageal Squamous Cell Carcinoma 22Carcinoma, Hepatocellular 21Triple Negative Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Breast Neoplasms 17Advanced Solid Tumor 17Stomach Neoplasms 14Melanoma 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Head and Neck Neoplasms 7Urinary Bladder Neoplasms 5Rectal Neoplasms 5Esophageal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4

Interventions

Gemcitabine 677130-nm albumin-bound paclitaxel 197Fluorouracil 184Oxaliplatin 173Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 129Irinotecan 111Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 71Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 48Magnetic Resonance Spectroscopy 45folfirinox 42Docetaxel 41Cetuximab 40irinotecan sucrosofate 36Specimen Handling 36S 1 (combination) 36Biopsy 30Radiation 29Paclitaxel 29Ipilimumab 27Surgical Procedures, Operative 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × toripalimab × Clear all
NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06577532 2025-05-21

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

Ruijin Hospital

Phase EARLY_PHASE1 Recruiting
56 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06370754 2024-04-17

FD-IMPACT

Fudan University

Phase 1/2 Not yet recruiting
117 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06080854 2023-10-12

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Not yet recruiting
108 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡